Insitro vs ConcertAI

Side-by-side comparison of AI visibility scores, market position, and capabilities

ConcertAI leads in AI visibility (74 vs 34)
Insitro logo

Insitro

EmergingBiotechnology

ML Drug Discovery

Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets for predicting drug targets and clinical outcomes in neurology, metabolic, and oncology programs.

AI VisibilityBeta
Overall Score
D34
Category Rank
#183 of 198
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
39
Gemini
36

About

Insitro is a drug discovery company founded in 2018 by Daphne Koller, a pioneer in machine learning and computational biology, having raised over $400M to build an integrated ML and biology platform. The company generates large-scale biological datasets using automated laboratory systems and human induced pluripotent stem cell models of disease, then trains machine learning models on this data to predict drug targets, patient stratification, and clinical outcomes. Unlike companies that apply ML to existing datasets, Insitro builds proprietary biological datasets specifically designed to train predictive models for drug discovery. The platform is being applied to neurological diseases, metabolic disorders, and oncology with the goal of identifying drug candidates more likely to succeed in clinical trials. Insitro has established partnerships with major pharmaceutical companies including Gilead Sciences and Bristol Myers Squibb to co-develop drugs using the platform. The company represents a model for how ML can be deeply integrated into pharmaceutical R&D rather than applied as a surface-level analytical layer.

Full profile
ConcertAI logo

ConcertAI

LeaderLife Sciences & BioTech

Oncology AI & Real-World Data

ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.

AI VisibilityBeta
Overall Score
B74
Category Rank
#2 of 198
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
69
Gemini
70

About

ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.

Full profile

AI Visibility Head-to-Head

34
Overall Score
74
#183
Category Rank
#2
77
AI Consensus
80
stable
Trend
stable
34
ChatGPT
73
39
Perplexity
69
36
Gemini
70
36
Claude
70
29
Grok
77

Key Details

Category
ML Drug Discovery
Oncology AI & Real-World Data
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Insitro
ML Drug Discovery

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.